CurrentRheuma
Get Weekly

CurrentRheuma coverage · page 4 of 5

The Lancet Rheumatology

Briefs 121–160 of 184 CurrentRheuma has covered from this journal, newest publication first

Latest from The Lancet Rheumatology

All coverage, newest first

  1. Lancet Rheumatol

    Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    Meta-analysisVasculitis & PMR

  2. Lancet Rheumatol

    Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

    Randomized controlled trial

  3. Lancet Rheumatol

    Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial

    Randomized controlled trialLupus & APS

  4. Lancet Rheumatol

    The Florida Scoring System for stratifying children with suspected Sjögren's disease: a cross-sectional machine learning study

    Cross-sectional studyPediatric

  5. Lancet Rheumatol

    Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial

    Randomized controlled trialRA

  6. Lancet Rheumatol

    Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study

    Cohort studyVasculitis & PMR

  7. Lancet Rheumatol

    Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

    Cross-sectional studySjögren's & overlap

  8. Lancet Rheumatol

    Global, regional, and national burden of neck pain, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

    Research articleFibromyalgia & pain

  9. Lancet Rheumatol

    Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls

    Research articleGout & crystals

  10. Lancet Rheumatol

    A preoperative package of care for osteoarthritis, consisting of weight loss, orthotics, rehabilitation, and topical and oral analgesia (OPPORTUNITY): a two-centre, open-label, randomised controlled feasibility trial

    Randomized controlled trialOsteoarthritis

  11. Lancet Rheumatol

    Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

    Secondary analysisAcross diseases

  12. Lancet Rheumatol

    Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium's international and multidisciplinary consensus recommendations

    Guideline or statementFibromyalgia & pain

  13. Lancet Rheumatol

    Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial

    Randomized controlled trialAutoinflammatory & rare

  14. Lancet Rheumatol

    Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study

    Cohort studyRA

  15. Lancet Rheumatol

    Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial

    Randomized controlled trialLupus & APS

  16. Lancet Rheumatol

    Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial

    Randomized controlled trialRA

  17. Lancet Rheumatol

    Hip-focused physical therapy versus spine-focused physical therapy for older adults with chronic low back pain at risk for mobility decline (MASH): a multicentre, single-masked, randomised controlled trial

    Randomized controlled trialFibromyalgia & pain

  18. Lancet Rheumatol

    Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study

    Cross-sectional studyLupus & APS

  19. Lancet Rheumatol

    Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

    Randomized controlled trialAcross diseases

  20. Lancet Rheumatol

    Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial

    Randomized controlled trialFibromyalgia & pain

  21. Lancet Rheumatol

    Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial

    Randomized controlled trialVasculitis & PMR

  22. Lancet Rheumatol

    Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline

    Guideline or statement

  23. Lancet Rheumatol

    Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial

    Cohort studyAcross diseases

  24. Lancet Rheumatol

    Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis

    Meta-analysisSpondyloarthritis & PsA

  25. Lancet Rheumatol

    Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study

    Cohort studyVasculitis & PMR

  26. Lancet Rheumatol

    Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study

    Cohort studyVasculitis & PMR

  27. Lancet Rheumatol

    Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial

    Randomized controlled trialSystemic sclerosis

  28. Lancet Rheumatol

    Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

    Randomized controlled trialRA

  29. Lancet Rheumatol

    Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

    Research articleRA

  30. Lancet Rheumatol

    MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study

    Cohort studySystemic sclerosis

  31. Lancet Rheumatol

    Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study

    Cohort studyLupus & APS

  32. Lancet Rheumatol

    Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY

    Cohort studyGout & crystals

  33. Lancet Rheumatol

    Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021

    Research articleOsteoarthritis

  34. Lancet Rheumatol

    Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

    Randomized controlled trial

  35. Lancet Rheumatol

    Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

    Randomized controlled trialRA

  36. Lancet Rheumatol

    Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial

    Randomized controlled trialGout & crystals

  37. Lancet Rheumatol

    Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY

    Cross-sectional studyAcross diseases

  38. Lancet Rheumatol

    Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

    Research articleAutoinflammatory & rare

  39. Lancet Rheumatol

    The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

    Secondary analysisVasculitis & PMR

  40. Lancet Rheumatol

    Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis

    Guideline or statementVasculitis & PMR

All 184 Briefs in ExploreShowing Briefs 121–160 of 184, newest first